Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa
source: The New England Journal of Medicine
year: 2020
authors: Chandy C. John, Robert O. Opoka, Teresa S. Latham, Heather A. Hume, Catherine Nabaggala, Phillip Kasirye, Christopher M. Ndugwa, Adam Lane, Russell E. Ware
summary/abstract:Background:
Hydroxyurea has proven safety, feasibility, and efficacy in children with sickle cell anemia in sub-Saharan Africa, with studies showing a reduced incidence of vaso-occlusive events and reduced mortality. Dosing standards remain undetermined, however, and whether escalation to the maximum tolerated dose confers clinical benefits that outweigh treatment-related toxic effects is unknown.
Methods:
In a randomized, double-blind trial, we compared hydroxyurea at a fixed dose (approximately 20 mg per kilogram of body weight per day) with dose escalation (approximately 30 mg per kilogram per day). The primary outcome was a hemoglobin level of 9.0 g or more per deciliter or a fetal hemoglobin level of 20% or more after 24 months. Secondary outcomes included the incidences of malaria, vaso-occlusive crises, and serious adverse events.
Results:
Children received hydroxyurea at a fixed dose (94 children; mean [±SD] age, 4.6±1.0 years) or with dose escalation (93 children; mean age, 4.8±0.9 years); the mean doses were 19.2±1.8 mg per kilogram per day and 29.5±3.6 mg per kilogram per day, respectively. The data and safety monitoring board halted the trial when the numbers of clinical events were significantly lower among children receiving escalated dosing than among those receiving a fixed dose. At trial closure, 86% of the children in the dose-escalation group had reached the primary-outcome thresholds, as compared with 37% of the children in the fixed-dose group (P<0.001). Children in the dose-escalation group had fewer sickle cell-related adverse events (incidence rate ratio, 0.43; 95% confidence interval [CI], 0.34 to 0.54), vaso-occlusive pain crises (incidence rate ratio, 0.43; 95% CI, 0.34 to 0.56), cases of acute chest syndrome or pneumonia (incidence rate ratio, 0.27; 95% CI, 0.11 to 0.56), transfusions (incidence rate ratio, 0.30; 95% CI, 0.20 to 0.43), and hospitalizations (incidence rate ratio, 0.21; 95% CI, 0.13 to 0.34). Laboratory-confirmed dose-limiting toxic effects were similar in the two groups, and there were no cases of severe neutropenia or thrombocytopenia.
Conclusions:
Among children with sickle cell anemia in sub-Saharan Africa, hydroxyurea with dose escalation had superior clinical efficacy to that of fixed-dose hydroxyurea, with equivalent safety.
DOI: 10.1056/NEJMoa2000146.
read more full text
Related Content
-
Integration of Mobile Health Into Sickle Cell Disease Care to Increase Hydroxyurea Utilization: Protocol for an Effi...Background: Hydroxyurea prevents disea...
-
The Hazards of Hazardous Drug Labeling: Time to Revisit Hydroxyurea?Despite benefits in reducing pain crises...
-
Effort set to help sickle cell patients manage medsVanderbilt University Medical Center is ...
-
Don’t Let Sickle Cell Disease Limit Youhttps://www.onescdvoice.com/wp-content/u...
-
Hydroxyurea and Sickle Cell Disease: A HRSA EMBRACE Projecthttps://www.youtube.com/watch?v=AyMP3P9E...
-
SCD Patients Receiving Hydroxyurea in the U.S. Still Face Many ChallengesPeople with sickle cell disease (SCD) tr...
-
Hydroxyurea Treatment in Men with SCA Leads to Drop in Total Sperm Count, Study ShowsResearchers found that treatment with hy...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.